SYK Targeting Represents a Potential Therapeutic Option for Relapsed Resistant Pediatric ETV6-RUNX1 B-Acute Lymphoblastic Leukemia PatientsValentina Serafin(University of Padua), Benedetta Accordi(University of Padua)International Journal of Molecular SciencesDecember 7, 201910.3390/ijms20246175Cited by 10SaveCiteExport RISWatch citationsRelated PapersFunctional Protein Network Activation Mapping Reveals New Potential Molecular Drug Targets for Poor Prognosis Pediatric BCP-ALL|PLoS ONE|2010|48